Login to Your Account

Janssen, GSK showcase one-year RA data for sirukumab

By Michael Fitzhugh
Staff Writer

Thursday, June 15, 2017

A pivotal study of the RA candidate sirukumab in patients whose needs aren’t met by standard RA therapies has shown that a year of treatment with the anti-interleukin (IL)-6 antibody improved the signs and symptoms of moderate to severe RA.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription